ArticleInternational journal of immunopathology and pharmacology
The COVID-19 vaccination experience in Bangladesh: Findings from a cross-sectional study.
Article in International journal of immunopathology and pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- High coverage and equitable distribution of COVID-19 vaccine uptake in two vulnerable areas in Bangladesh.PLOS global public health · 2025Article
- Review
- Experience and side effects of COVID-19 vaccine uptake among university students: a cross-sectional survey study.Frontiers in public health · 2024Article
- COVID-19 vaccination uptake in remote areas-Evidence from a panel survey in Bangladesh.PloS one · 2024Article
- A review of SARS-CoV-2 variants and vaccines: Viral properties, mutations, vaccine efficacy, and safety.Infectious medicine · 2023Review
- Article
- A quantitative evaluation of the impact of vaccine roll-out rate and coverage on reducing deaths: insights from the first 2 years of COVID-19 epidemic in Iran.BMC medicine · 2023Article
- Assessment of risk perception and subjective norms related to Mpox (monkeypox) among adult males in Bangladesh: A cross-sectional study.Health science reports · 2023Article
- Risk evaluation and mitigation strategies for newly detected SARS-CoV-2 Omicron BF.7 subvariant: A brief report.Health science reports · 2023Article
- Article
- COVID-19 vaccination in the mass vaccination center: clinical practice and effectiveness analysis.Frontiers in public health · 2023Article
- Evaluation of COVID-19 vaccine acceptance and uptake in rural Bangladesh: a cross-sectional study.BMJ open · 2022Article
- Increasing reinfections and decreasing effectiveness of COVID-19 vaccines urge the need for vaccine customization.Annals of medicine and surgery (2012) · 2022Article
- Burden of COVID-19 on health and wellbeing, education, and economy of Bangladesh.Clinical case reports · 2022Article
- Article
- Prevalence and associated factors for elevated fear and depressive symptoms among the private service holders in Bangladesh during the Covid-19 pandemic: A cross-sectional study.Health science reports · 2022Article
- A systematic review and meta-analysis of abnormalities in hematological and biochemical markers among Bangladeshi COVID-19 cases.Health science reports · 2022Article
- Comparative evaluation of authorized drugs for treating Covid-19 patients.Health science reports · 2022Article
- The SARS-CoV-2 Omicron (B.1.1.529) variant and the re-emergence of COVID-19 in Europe: An alarm for Bangladesh.Health science reports · 2022Article
- Chinese University Students' Awareness and Acceptance of the COVID-19 Vaccine: A Cross-Sectional Study.Risk management and healthcare policy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesVaccination rollout against COVID-19 has started in developed countries in early December 2020. Mass immunization for poor or low-income countries is quite challenging before 2023. Being a lower-middle-income country, Bangladesh has begun a nationwide COVID-19 vaccination drive in early February 2021. Here, we aimed to assess the opinions, experiences, and adverse events of the COVID-19 vaccination in Bangladesh.
methodsWe conducted this online cross-sectional study from 10 February 2021, to 10 March 2021, in Bangladesh. A self-reported semi-structured survey questionnaire was used using Google forms. We recorded demographics, disease history, medication records, opinions and experiences of vaccination, and associated adverse events symptoms.
resultsWe observed leading comorbid diseases were hypertension (25.9%), diabetes (21.1%), heart diseases (9.3%), and asthma (8.7%). The most frequently reported adverse events were injection site pain (34.3%), fever (32.6%), headache (20.2%), fatigue (16.6%), and cold feeling (15.4%). The chances of having adverse events were significantly higher in males than females (
conclusionAccording to the present findings, reported adverse events after the doses of Covishield in Bangladesh were non-serious and temporary. In Bangladesh, the early vaccination against COVID-19 was possible due to its prudent vaccine deal, previous mass vaccination experience, and vaccine diplomacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.